Skip to main content

The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer (2019)
Journal Article
Jones, D., Wilson, L., Thomas, H., Gaughan, L., & Wade, M. (in press). The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer. Cancers, 11(8), https://doi.org/10.3390/cancers11081122

Many estrogen receptor (ER)-positive breast cancers develop resistance to endocrine therapy but retain canonical receptor signalling in the presence of selective ER antagonists. Numerous co-regulatory proteins, including enzymes that modulate the chr... Read More about The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer.

The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart (2019)
Journal Article
Onwuli, D. O., Samuel, S., Sfyri, P., Welham, K., Goddard, M., Abu-Omar, Y., …Beltran-Alvarez, P. (2019). The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart. International journal of cardiology, 282, 76-80. https://doi.org/10.1016/j.ijcard.2019.01.102

Background The inhibitory subunit of cardiac troponin (cTnI) is a gold standard cardiac biomarker and also an essential protein in cardiomyocyte excitation-contraction coupling. The interactions of cTnI with other proteins are fine-tuned by post-tra... Read More about The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart.

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition (2015)
Journal Article
Middleton, F. K., Patterson, M. J., Elstob, C. J., Fordham, S., Herriott, A., Wade, M. A., …Curtin, N. J. (2015). Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget, 6(32), doi:10.18632/oncotarget.6136

ATR is an attractive target in cancer therapy because it signals replication stress and DNA lesions for repair and to S/G2 checkpoints. Cancer-specific defects in the DNA damage response (DDR) may render cancer cells vulnerable to ATR inhibition alon... Read More about Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.

FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer (2015)
Journal Article
Jones, D., Wade, M., Nakjang, S., Chaytor, L., Grey, J., Robson, C. N., & Gaughan, L. (2015). FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Oncotarget, 6(30), 29782-29794. doi:10.18632/oncotarget.4927

Retention of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the requirement for the development of more effective AR targeting therapies. A key mechanism of resistance to anti-androgens is through expression... Read More about FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy (2015)
Journal Article
O’Neill, D., Jones, D., Wade, M., Grey, J., Nakjang, S., Guo, W., …Gaughan, L. (2015). Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. Oncotarget, 6(28), 26029-26040. doi:10.18632/oncotarget.4347

The persistence of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the unmet clinical need for the development of more effective AR targeting therapies. A key mechanism of therapy-resistance is by selection o... Read More about Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.

c-MYC is a radiosensitive locus in human breast cells (2014)
Journal Article
Wade, M. A., Sunter, N. J., Fordham, S. E., Long, A., Masic, D., Russell, L. J., …Allan, J. M. (2015). c-MYC is a radiosensitive locus in human breast cells. Oncogene, 34(38), 4985-4994. doi:10.1038/onc.2014.427

Ionising radiation is a potent human carcinogen. Epidemiological studies have shown that adolescent and young women are at increased risk of developing breast cancer following exposure to ionising radiation compared with older women, and that risk is... Read More about c-MYC is a radiosensitive locus in human breast cells.

The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer (2014)
Journal Article
Wade, M. A., Jones, D., Wilson, L., Stockley, J., Coffey, K., Robson, C. N., & Gaughan, L. (2015). The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer. Nucleic Acids Research, 43(1), 196-207. doi:10.1093/nar/gku1298

Endocrine therapy has successfully been used to treat estrogen receptor (ER)-positive breast cancer, but this invariably fails with cancers becoming refractory to treatment. Emerging evidence has suggested that fluctuations in ER co-regulatory protei... Read More about The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.

KDM4B is a master regulator of the estrogen receptor signalling cascade (2013)
Journal Article
Gaughan, L., Stockley, J., Coffey, K., O’Neill, D., Jones, D. L., Wade, M., …Robson, C. N. (2013). KDM4B is a master regulator of the estrogen receptor signalling cascade. Nucleic Acids Research, 41(14), 6892-6904. doi:10.1093/nar/gkt469

The importance of the estrogen receptor (ER) in breast cancer (BCa) development makes it a prominent target for therapy. Current treatments, however, have limited effectiveness, and hence the definition of new therapeutic targets is vital. The ER is... Read More about KDM4B is a master regulator of the estrogen receptor signalling cascade.

Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant (2011)
Journal Article
Al-Balool, H. H., Weber, D., Liu, Y., Wade, M., Guleria, K., Nam, P. L. P., …Jackson, M. S. (2011). Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant. Genome research, 21(11), 1788-1799. doi:10.1101/gr.116442.110

In silico analyses have established that transcripts from some genes can be processed into RNAs with rearranged exon order relative to genomic structure (post-transcriptional exon shuffling, or PTES). Although known to contribute to transcriptome div... Read More about Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant.


;